glp 1 egfr cut off Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs Journal of Lancaster General Health

BioWorld - Saturday, July 25, 2026 Breaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaSee today's BioWorld Science Home Phase II study confirms the therapeutic benefits of AOD-9604 in obesity To read the full story, subscribe or sign in

This effect is particularly relevant in the context of chronic inflammation, where barrier dysfunction contributes to disease progression

The hazard ratio was elevated in the crude analysis comparing GLP-1 receptor agonists with SGLT-2 inhibitors (hazard ratio 1.60, 95% CI 1.37 to 1.87) but null after adjustment for confounding (weighted incidence rate 4.3 (95% CI 3.8 to 4.9) v 4.6 (4.3 to 4.9), respectively

(Adapted from Goldstein et al., 2005

Your nurse will recommend a safer option or hold off on treatment

Saxagliptin is part of a class of medications called DPP-4 inhibitors